x

Medicines Co, Alnylam Pharma enter alliance

Print Page Updated: 06:24:19 PM, Mon 04 February 2013
PARSIPPANY, N.J. (AP) — Drugmaker Medicines Co. is entering an alliance with Alnylam Pharmaceuticals Inc. to help develop the biopharmaceutical company's RNA interference drugs that could potentially help lower cholesterol.

Alnylam's drugs use RNA interference, or RNAi, technology. RNAi therapies work by turning off or silencing disease-causing genes.

Under terms of the exclusive alliance, Medicines will make a $25 million upfront cash payment to Alnylam. There is also the potential for up to $180 million in development and commercial payments if certain milestones are met.

Medicines is based in Parsippany, N.J. Alnylam is based in Cambridge, Mass.

Medicines' stock fell 42 cents to $30.11 in afternoon trading, while shares of Alnylam declined 57 cents, or 2.4 percent, to $23.67.

Tags: alnylam, alnylam pharmaceuticals inc., drugmaker medicines co., science_technology, cents, medicine, development, technology, percent, afternoon trading, terms, parsippany, alliance, stock, shares, virus, potential, payment, drug, pharmacology, pharmaceutical drug, rna, biopharmaceutical company, rnai therapies, disease-causing genes, medicines, alnylam pharma enter, rna interference, n.j. alnylam, rna interference drugs, upfront cash payment, lower cholesterol, certain milestones, commercial payments, exclusive alliance

Close
Loading

News Headlines.com

  • List View
  • Grid View
Close
Contact Us
Send Feedback X